Spots Global Cancer Trial Database for Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
Official Title: Phase I, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of Icotinib Combined With Gemcitabine as First-line Treatment in Locally Advanced, Unresectable or Metastatic Pancreatic Cancer
Study ID: NCT02278458
Conditions
Study Description
Brief Summary: Research Hypothesis: icotinib administered in combination with gemcitabine has an acceptable safety profile in subjects with locally advanced, unresectable or metastatic pancreatic adenocarcinoma.The primary objective is to determine the safety profile of icotinib in combination with gemcitabine in subjects with locally advanced, unresectable or metastatic pancreatic adenocarcinoma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Bethune First Hospital of Jilin University, Changchun, Jilin, China
First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
Contact Details
Name: Yanqiao Zhang, MD
Affiliation: Cancer Hospital of Harbin Medical University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
